CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-19 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −12,008 | $22.30 | $268K | 903,180 |
| 2025-11-19 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −492 | $23.09 | $11K | 902,688 |
| 2025-11-17 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −12,500 | $21.82 | $273K | 890,392 |
| 2025-11-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −6,054 | $17.35 | $105K | 270,587 |
| 2025-11-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −613 | $17.94 | $11K | 269,974 |
| 2025-10-20 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −12,500 | $22.08 | $276K | 915,188 |
| 2025-10-17 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −12,500 | $21.33 | $267K | 902,892 |
| 2025-10-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −6,667 | $20.10 | $134K | 276,641 |
| 2025-09-29 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,250 | $2.48 | $8K | 26,250 |
| 2025-09-29 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,250 | $20.40 | $66K | 23,000 |
| 2025-09-29 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,250 | 105,056 | ||
| 2025-09-26 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −3,700 | $20.06 | $74K | 915,392 |
| 2025-09-26 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −4,000 | $20.25 | $81K | 927,688 |
| 2025-09-23 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −2,800 | $20.03 | $56K | 919,092 |
| 2025-09-23 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −1,500 | $20.03 | $30K | 931,688 |
| 2025-09-19 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −4,870 | $19.11 | $93K | 935,318 |
| 2025-09-19 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −2,130 | $20.02 | $43K | 933,188 |
| 2025-09-19 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −1,000 | $20.25 | $20K | 921,892 |
| 2025-09-17 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −5,000 | $19.09 | $95K | 922,892 |
| 2025-09-08 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −6,667 | $20.24 | $135K | 283,308 |
Page 8 of 37 · 724 trades